In year 2012, The Oncogenetics and Hereditary Cancer Coordination Center was established at Vilnius University Hospital Santaros Klinikos (VUH SK). Later on, in 2015, this center was reorganized into the Reference Center of Hereditary Cancer (RCHC). The Head of the center is dr. Ramunas Janavicius.

VUH SK Outpatient Clinic (Santariskiu st. 2, Vilnius) provides outpatient specialized genetic counseling on hereditary predisposition to cancer (oncogenetic consultation specialized in hereditary cancer - breast, ovarian, colon - and other rare genetic syndromes). Oncogenetic molecular tests of hereditary cancer using new diagnostic technologies (ex. Next Generation Sequencing) are performed in the Laboratory of Molecular Medicine, Center for Hematology, Oncology and Transfusion, belonging to VUH SK.

VUH SK Hereditary Cancer Reference Center is the only place in Lithuania and the Baltic States specializing in hereditary cancer and providing the widest range of genetic testing and care services (since 2007). Over 1000 individuals with genetically confirmed predispositions to oncological diseases are followed in an electronic patient monitoring system, about 700 molecular genetic tests and 1000 oncogenetic consultations are performed yearly.


Reference Center of Hereditary Cancer is the only place in the country for the most comprehensive genetic predisposition for cancer and specialized oncogenetic counseling:

  • Inherited predisposition to breast cancer: gene studies of BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, BRIP1, PALB2, RAD51C, RAD51D, CHEK2, ATM, NBN, BLM, FANCM, NF1.

  • Inherited predisposition to ovarian cancer: gene studies of BRCA1, BRCA2, TP53, STK11, BRIP1, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, FANCM.

  • Hereditary predisposition for bowel cancer: MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11, SMAD4, BMPR1A, TP53, CHEK2 genes.

  • Inherited predisposition to kidney cancer: VHL, MET, FLCN, FH, PTEN, TSC1, TSC2, SDHB, SDHD, WT1, BAP1 gene studies.

  • Adrenal pheochromocytomas / paragangliomas: VHL, RET, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX, NF1, FH gene studies

  • Inherited predisposition to gastric cancer: CDH1, APC, BMPR1, MLH1, MSH2, MSH6, PMS2, EPCAM, PDGFRA, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53 genes.

  • Inherited predisposition to pancreatic cancer: APC, BMPR1A, BRCA1, BRCA2, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, PMS2, PALB2, SMAD4, STK11, TP53, TSC1, TSC2, VHL gene studies.

  • Hereditary predisposition to other cancers (sarcoma, thyroid, skin (melanoma), prostate cancer, brain cancer, etc.) and rare oncogenetic syndromes (Tuberous Sclerosis Complex (TSC1, TSC2), Neurofibromatosis (Type I and II), Retinoblastoma, Multiple Neuroendocrine glandular syndromes, etc.)

International cooperation
Our centre actively cooperates with foreign scientists in the field of hereditary cancer. Dr. R. Janavicius is a Principal Investigator at the Consortium of Researchers of the Temporary BRCA1 / 2 Gene Modifiers (University of Cambridge, UK / University of Queensland, Australia); Founder of Lithuanian-Latvian Hereditary Breast and Ovarian Cancer Consortium (Baltic Familial Breast-Ovarian Cancer Consortium). Collaboration with Dresden University of Technology (Germany), Milan Cancer Institute (Italy), Manchester and Cambridge University (UK), etc.
Last edited: 2021-03-29
To the top